YOU ARE EXPLORING
Oncology Biomarkers EGFR / ALK / ROS1
Cancer biomarkers | From findings to interpretation

EGFR / ALK / ROS1

Actionable oncogenic drivers in NSCLC: initial testing, acquired resistance, tissue stewardship, and methods for detecting fusions.

Clinical context

Biomarker definition and clinical relevance

Molecular-driver assessment is an essential part of advanced NSCLC evaluation before systemic treatment. EGFR is a receptor tyrosine kinase, whereas ALK and ROS1 rearrangements usually produce activating fusions. These alterations affect targeted-therapy selection independently of PD-L1 expression.

Note for clinicians

Final decisions depend on tumor type, stage, previous therapy, a validated assay result, and current drug indications. This content does not imply availability of a bookable laboratory service.

CLINICAL APPLICATIONS

Clinical applications and result interpretation

01

First-line treatment in advanced NSCLC

Evaluate EGFR exon 19 deletions, L858R, exon 20 insertions, ALK fusions, and ROS1 fusions at diagnosis to select variant-specific therapy according to stage, prior treatment, and current guidance.

Assay and specimen: Broad validated DNA NGS on FFPE tissue, supplemented with RNA-based fusion assays where appropriate; validated ALK IHC and orthogonal confirmation as indicated.

Clinical interpretation: Report the precise EGFR variant, fusion characteristics, prior tyrosine-kinase inhibitor exposure, and central nervous system involvement.

02

Acquired resistance and progression

At progression under tyrosine-kinase inhibitors, repeat testing can reveal secondary mutations, bypass alterations, or histologic transformation and may influence subsequent management.

Assay and specimen: Tissue re-biopsy where feasible; validated plasma ctDNA as a complementary approach when tissue access is limited.

Clinical interpretation: Negative plasma ctDNA does not exclude a resistance mechanism, particularly in low-shedding tumors. Tissue-based reassessment may be needed.

03

Test sequencing and tissue preservation

Coordinate required testing in small lung biopsies to reduce tissue depletion and delays in treatment decisions.

Assay and specimen: Document tumor fraction, panel depth and coverage, fusion-detection capability, and complementary DNA/RNA methods.

Clinical interpretation: PD-L1 alone is insufficient; assess relevant EGFR alterations and fusions before relying on first-line immunotherapy selection.

INTERPRETATION / LIMITATIONS

Limitations and interpretive notes

• EGFR variants are not therapeutically interchangeable; always report the exon and specific alteration.

• DNA-only NGS can miss some ALK/ROS1 rearrangements, particularly complex fusions; RNA analysis can complement it.

• When interpreting negative ctDNA, consider false negatives due to low shedding and possible clonal hematopoiesis artifacts.

REFERENCES

Guidelines and references

Discuss a specific molecular scenario

For questions about a clinical scenario, use the support form without including any patient identifiers.

Specialist support form →
WhatsAppCall usGet expert consultation